



## Curative Prevention and Treatment for Hepatocellular Carcinoma

Guest Editor:

**Dr. Katsunori Yoshida**

Department of Gastroenterology  
and Hepatology, Kansai Medical  
University, Osaka 573-1191,  
Japan

Deadline for manuscript  
submissions:

**closed (15 June 2023)**

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) is a highly prevalent malignant tumor, which usually develops in patients with chronic liver disease. The prognosis of HCC at an early stage has improved considerably in recent years. However, the prognosis of unresectable advanced HCC is still unsatisfactory. The MAPK and PI3K cascades, which are signaling pathways responsible for inhibition of cell proliferation, angiogenesis, or cell death, are characterized by the presence of tyrosine kinase activity at the upstream receptors for growth factors, and many molecular targeted therapies are designed to inhibit tyrosine kinase activity. Molecular targeted therapy for liver cancer has just begun, and there are various issues that need to be resolved. One example is the identification of biomarkers to confirm the safety of long-term administration and to predict the therapeutic effect. In addition, further elucidation of the mechanism of hepatocarcinogenesis and development of more specific molecular targeted therapeutics are also awaited.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)